Financial Review: Dermata Therapeutics (NASDAQ:DRMA) and Biogen (NASDAQ:BIIB)

Dermata Therapeutics (NASDAQ:DRMA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 18.5% of Dermata Therapeutics shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Dermata Therapeutics and Biogen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$12.29 million	($7.81)	-0.16
Biogen	$9.89 billion	2.74	$1.29 billion	$8.81	20.98

Biogen has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dermata Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Dermata Therapeutics and Biogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1	0	1	0	2.00
Biogen	0	15	12	0	2.44

Dermata Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 700.00%. Biogen has a consensus target price of $205.04, suggesting a potential upside of 10.91%. Given Dermata Therapeutics’ higher probable upside, research analysts clearly believe Dermata Therapeutics is more favorable than Biogen.

Profitability

This table compares Dermata Therapeutics and Biogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-191.95%	-140.15%
Biogen	13.07%	12.64%	7.81%

Summary

Biogen beats Dermata Therapeutics on 10 of the 13 factors compared between the two stocks.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.